Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Analyst Perspectives | Gain insights from varied analyst targets, ranging from $96 to $155, reflecting diverse views on Merck's growth potential and market positioning |
Global Market Challenges | Uncover the complexities Merck faces in international markets, particularly the Gardasil sales pause in China, and its implications for future revenue streams |
Pipeline Potential | Delve into Merck's promising R&D pipeline, including clesrovimab and MK-4082, and their potential to offset future patent expirations and drive growth |
Keytruda's Dominance | Explore Merck's strategic positioning in oncology, driven by Keytruda's success and the potential impact of its new subcutaneous formulation on market leadership |
Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
---|---|---|---|---|
P/E Ratio | 11.9x | −2.8x | −0.5x | |
PEG Ratio | 0.02 | 0.00 | 0.00 | |
Price / Book | 4.5x | 0.6x | 2.6x | |
Price / LTM Sales | 3.3x | 4.4x | 2.9x | |
Upside (Analyst Target) | 26.9% | 56.7% | 57.1% | |
Fair Value Upside | Unlock | 13.4% | 9.0% | Unlock |